HIF1A and hereditary hemorrhagic telangiectasia: We found that Roxadustat, which inhibits HIF hydroxylation through prolyl hydroxylases and degradation through the proteasome and thus stabilizes HIF-1α protein, significantly increased HIF-1α protein in PBMCs from HHT patients (Figure 3).